| COVANCE STRENGTHENS NONCLINICAL SAFETY ASSESSMENT MANAGEMENT TEAM |
 |
Princeton, New Jersey, January 14, 2003 — Covance Inc. (NYSE: CVD), is pleased to announce that Steven Barkyoumb, DVM, PhD, has joined the company as the Senior Director of Pathology, North American Toxicology Services. Dr. Barkyoumb will be responsible for the overall leadership and direction of clinical and anatomic pathology operations at Covance's Madison, Wisconsin and Vienna, Virginia nonclinical development facilities. These facilities contribute to Covance's global leadership position in providing nonclinical contract safety assessment services to the pharmaceutical industry.
Dr. Barkyoumb brings to Covance over 18 years of nonclinical safety assessment experience as a toxicological pathologist and toxicologist. Most recently, Dr. Barykoumb was the Executive Director of Nonclinical Drug Safety at Quintiles Transnational, where he was responsible for the management and growth of their Toxicology, Safety Pharmacology and Laboratory Animal Services. His prior experience also includes director level positions with Abbott Laboratories, Midwest Research Institute, Hoechst Marion Roussel and Marion Merrell Dow, Inc. Dr. Barkyoumb holds doctoral and DVM degrees from Kansas State and is a diplomat of the American College of Veterinary Pathologists and the American Board of Toxicology. He has extensive industry experience in toxicological pathology and in the design, conduct and interpretation of nonclinical safety assessment studies.
"Our scientists provide much of the underlying scientific data regarding how drug candidates affect humans and enable drug makers to make quicker commercial decision-making through our rapid delivery of the data. Dr. Barkyoumb will be an excellent addition to our scientific and management staff," said Dr. Ronald Marler, Senior Director of North American Toxicology. "Dr Barkyoumb's credentials, industry experience, and proven management record will add to the foundation of quality pathology services the pharmaceutical industry has come to expect from Covance."
Dr. Barykoumb's hire coincides with the recent completion of Covance's $27 million North American toxicology expansion project, adding 45 animal rooms and over 60 scientific, technical and support staff to the nonclinical development sites in Madison, Wisconsin and Vienna, Virginia. The addition of Dr. Barkyoumb and increase in toxicology capacity further strengthens Covance's commitment to the pharmaceutical industry by providing superior science with improved flexibility in scheduling studies to meet the industry's project milestones.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with 2001 pro forma revenues of $800 million, operations currently in 17 countries, and approximately 6,900 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through the website in the About Covance area. |
|
|
